| Autor: |
Ong SJ; Addenbrookes Hospital, Cambridge Universities Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK., Sharkey LM; Addenbrookes Hospital, Cambridge Universities Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK., Low KE; Addenbrookes Hospital, Cambridge Universities Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK., Cheow HK; Addenbrookes Hospital, Cambridge Universities Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK., Butler AJ; Addenbrookes Hospital, Cambridge Universities Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK., Buscombe JR; Addenbrookes Hospital, Cambridge Universities Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK. |
| Abstrakt: |
Multivisceral transplant (MVTx) refers to a composite graft from a cadaveric donor, which often includes the liver, the pancreaticoduodenal complex, and small intestine transplanted en bloc. It remains rare and is performed in specialist centres. Post-transplant complications are reported at a higher rate in multivisceral transplants because of the high levels of immunosuppression used to prevent rejection of the highly immunogenic intestine. In this study, we analyzed the clinical utility of 28 18 F-FDG PET/CT scans in 20 multivisceral transplant recipients in whom previous non-functional imaging was deemed clinically inconclusive. The results were compared with histopathological and clinical follow-up data. In our study, the accuracy of 18 F-FDG PET/CT was determined as 66.7%, where a final diagnosis was confirmed clinically or via pathology. Of the 28 scans, 24 scans (85.7%) directly affected patient management, of which 9 were related to starting of new treatments and 6 resulted in an ongoing treatment or planned surgery being stopped. This study demonstrates that 18 F-FDG PET/CT is a promising technique in identifying life-threatening pathologies in this complex group of patients. It would appear that 18 F-FDG PET/CT has a good level of accuracy, including for those MVTx patients suffering from infection, post-transplant lymphoproliferative disease, and malignancy. |
